title: Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma.
abstract: Human liver-specific organic anion transporter-2 (LST-2/OATP8/SLCO1B3) has been demonstrated to be expressed in various gastrointestinal carcinomas and also to play pivotal roles in the uptake of a wide variety of both endogenous and exogenous anionic compounds, including bile acids, conjugated steroids and hormones, into hepatocytes in the human liver. However, the biological significance of LST-2 in human carcinomas remains unknown. In the present study, we examined the expression of LST-2 in 102 cases of breast carcinoma using immunohistochemistry and correlated the findings with various clinicopathological parameters in order to examine the possible biological and clinical significance of LST-2. LST-2 immunoreactivity was detected in 51 cases (50.0%); of these 51 positive cases, LST-2 immunoreactivity was inversely correlated with tumor size (P = 0.0289). In addition, LST-2 immunoreactivity was significantly associated with a decreased risk of recurrence and improved prognosis by both univariate (P = 0.02 and P = 0.01) and multivariate (P = 0.03 and P = 0.01) analyses. In the estrogen receptor-positive groups, the LST-2-positive patients showed good prognoses. Considering that LST-2 transports estrone-3-sulfate, these results suggest that LST-2 overexpression is associated with a hormone-dependent growth mechanism of the breast cancer. The results of our present study demonstrate that LST-2 immunoreactivity is a potent prognostic factor in human breast cancer.
authors.affiliation: Division of Gastroenterological Surgery, Tohoku University Graduate School of Medicine, Sendai 2980-8574, Japan.
authors.forename: Mitsuhisa
authors.initials: M
authors.lastname: Muto
authors.forename: Tohru
authors.initials: T
authors.lastname: Onogawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Takanori
authors.initials: T
authors.lastname: Ishida
authors.forename: Toshiki
authors.initials: T
authors.lastname: Rikiyama
authors.forename: Yu
authors.initials: Y
authors.lastname: Katayose
authors.forename: Noriaki
authors.initials: N
authors.lastname: Ohuchi
authors.forename: Hironobu
authors.initials: H
authors.lastname: Sasano
authors.forename: Takaaki
authors.initials: T
authors.lastname: Abe
authors.forename: Michiaki
authors.initials: M
authors.lastname: Unno
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D008099:Liver / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D029362:Organic Anion Transporters, Sodium-Independent / Q000378:metabolism*; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D000074542:Solute Carrier Organic Anion Transporter Family Member 1B3; D015996:Survival Rate
chemical_list: D029362:Organic Anion Transporters, Sodium-Independent; D011960:Receptors, Estrogen; C490280:SLC22A7 protein, human; C421209:SLCO1B3 protein, human; D000074542:Solute Carrier Organic Anion Transporter Family Member 1B3